Consensus Demant A/S Wiener Boerse

Equities

DEMA

DK0060738599

End-of-day quote Wiener Boerse Other stock markets 03:30:00 27/06/2024 am IST			5-day change	1st Jan Change
40.86 ^EUR	-1.49%		0.00%	+2.97%

26/06	Demant Flags Delay in Completion of Communications Business' Strategic Review	MT
29/05	UK’s Competition Regulator Closes Cochlear-Demant Deal	MT

Evolution of the average Target Price on Demant A/S

Price target over the last 5 years

History of analyst recommendation changes

63396ce4d6a7f8ebddf823d49f.2YvBq8f5AXqB8z3S4XIHosalzthTM9dudRwoOCrTH68.6r2Jk6amUwvKlVmzpz1rwKSc_qswYLwtMX8RdXXjeIKN0vaS6oFbM-rFcA~eb61b2e57ab17378ec3e97d7a537e67b

Analyst Recommendations on Demant A/S

DEMANT : Q1 sales miss; organic growth guidance unchanged	06/05
DEMANT : In-line Q4; markets cheer the promising takeaways for 2024	06/02
DEMANT : Sales broadly in-line; guidance narrowed	07/11
Chinese headwinds could be more severe than expected	22/23/22
DEMANT : Better-than-expected Q2 + a guidance upgrade	22/23/22
DEMANT : Better-than-expected Q2 + a guidance upgrade	16/23/16
DEMANT : New product launches + a rebound in hearing aids are encouraging	03/23/03
DEMANT : Strong Q1 + guidance upgrade	25/23/25
DEMANT : Strong Q1 + guidance upgrade	18/23/18
DEMANT : Strong Q4 + promising takeaways	05/23/05
DEMANT : Strong Q4 + promising takeaways	07/23/07
DEMANT : Soft Q3 + consecutive guidance downgrade	02/22/02
DEMANT : Soft Q2 + guidance downgrade	17/22/17
DEMANT : In line Q1, full year guidance reiterated	05/22/05
DEMANT : Hearing Healthcare recovery continues; capitalise the entry opportunity	09/22/09
DEMANT : Marginal guidance upgrade won’t trigger a change in stance	02/21/02
DEMANT : 2021 CMD: ambitious targets unveiled	29/21/29
DEMANT : As communications slows, hearing healthcare takes the lead; FY21 outlook upgraded	13/21/13
ANALYST RECOMMENDATIONS : American Express, HSBC, CyrusOne, Microsoft, Vodafone...	18/21/18
DEMANT : Better-than-expected operational performance ytd; FY21 targets raised	04/21/04
DEMANT : Pent-up demand visible in H2 20; ambitious guidance for FY21	10/21/10